



Australian Government
**Australian Radiation Protection
and Nuclear Safety Agency**



ACDS

Strategic Plan 2018–2022

Foreword

The Strategic Plan for the Australian Clinical Dosimetry Service (ACDS) is a living document which at a high level sets out the strategic objectives for the coming four years. It will be reviewed and as necessary revised annually, while maintaining its four-year outlook. The Strategic Plan forms the basis for the annual business plans and the review and revision of the strategic and operational risk register. The ACDS Strategic Plan is aligned with ARPANSA's four-year [*Corporate Plan*](#), notably ARPANSA's Strategic Objective 3: *Promote the safe and effective use of ionising radiation in medicine*.

We are confident that the dedicated and highly competent ACDS staff, with the support of ARPANSA's infrastructure, with advice from the ACDS Oversight Committee, and with advice from the Clinical Advisory Group, will continue to deliver quality services to the Australian health care system for the benefit of patient safety, as set out in this Strategic Plan.



Carl-Magnus Larsson
CEO of ARPANSA



Jessica Lye
ACDS Director



Vision for the ACDS

A world leading dosimetry audit service for the highest level of quality and patient safety in radiation therapy

The ACDS vision supports the ARPANSA vision:

A safe radiation environment for the Australian community



Mission of the ACDS

To guide, support and improve patient safety and radiotherapy service delivery by:

- providing a comprehensive suite of audit modalities covering all common clinical practices
- improving national dosimetry capabilities in clinical treatment delivery
- offering its services to Australian and overseas radiotherapy centres on a fee-for-service basis.

The mission of ACDS is fully aligned with Strategic Objective 3 of ARPANSA:

Promote the safe and effective use of radiation in medicine

Our strategic objectives

ACDS aspires to:



Be recognised as a global leader and associated with the highest standards of quality and safety in radiotherapy



Be the provider of auditing services to all Australian and New Zealand radiotherapy facilities



Be recognised as the leading dosimetry audit experts nationally and in the Asia-Pacific region



Offer competitive quality services that cover all clinical practices and emerging technologies



Positively influence the use of radiation in medicine and have tangible impact benefitting patient safety

Our strategies

The ACDS program of work entails five key strategies that guide our priorities and planning:



Expand our coverage of market and modalities



Offer value for money



Consolidate our reputation as trusted service provider



Influence the profession and the health care system



Develop robust and transparent governance

The strategies support the delivery of outputs and outcomes for the benefit of the Australian community. The key results areas and a selection of associated key performance indicators are given below. The risks encountered in realising the strategies are identified and managed in accordance with ARPANSA's Risk Management Framework and with broader requirements such as the Commonwealth Risk Management Policy 2014 and the international standard on risk management (*AS/NZS ISO 31000:2009*), and meets the requirements of Section 16 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

Our strategies	Key result areas	Key performance indicators
 <p>Market share</p>	<ul style="list-style-type: none"> • Provide a national audit service to Australian facilities • Participation of NZ facilities • Inclusion of new modalities 	<ul style="list-style-type: none"> • >95% Australian participation in 2018–2022 • ≥1 NZ facility in 2019 • ≥1 new modality per year
 <p>Value for money</p>	<ul style="list-style-type: none"> • Maintained focus on cost-effectiveness while sustaining service quality • Expand clinical coverage • Establishment of clinical trial linkage 	<ul style="list-style-type: none"> • Perform annual cost model review and ensure ACDS is sustainably funded through audit revenue • Provide audits that meets ROHPG and jurisdictional conditions • Evidence of TROG using ACDS audits
 <p>Reputation</p>	<ul style="list-style-type: none"> • Maintained and improved customer satisfaction • Leading dosimetry expertise • Brand recognition among all stakeholders 	<ul style="list-style-type: none"> • Year on year improvement in net promoter score in customer survey • ≥1 peer-reviewed scientific publications based on ACDS audits
 <p>Influence</p>	<ul style="list-style-type: none"> • Influence on domestic and regional best practice • Engagement and influence on international auditing practice • Influence in the broader health system 	<ul style="list-style-type: none"> • Participation in Global Harmonisation group activities • Instigate regional audit harmonisation group by 2020 • ≥3 invited or accepted to present at key professional fora
 <p>Governance</p>	<ul style="list-style-type: none"> • Continuous improvement of the management system • Transparent financial reporting • Refreshed clinical advisory group (CAG) • Proactive horizon scanning 	<ul style="list-style-type: none"> • AOC reports accepted by HSPC • Implementation of new management reporting system in 2019 • Confirmed operation of CAG within Terms of Reference each year